Welcome to PsychU!

APA Releases New Evidence-based Practice Guideline for Patients with Schizophrenia

Patients with schizophrenia should have documented, comprehensive, and person-centric treatment plans that include evidence-based nonpharmacologic and pharmacological treatments, according to …

You must be logged-in to view this content.

Foundations & Future Plans For Precision Medicine In The Treatment Of GAD

Generalized anxiety disorder (GAD) is a broad disorder marked by uncontrollable worry that affects daily life for at least six …

You must be logged-in to view this content.

Log In

Using Holistic Strategies To Improve Outcomes In Mood Disorders

Mood disorders are highly prevalent and a leading cause of disability in patients worldwide. Approved pharmacologic treatments are not adequate …

You must be logged-in to view this content.

Webinar Summary – The Role Of Glutamate In Mood Disorders & Schizophrenia

You must be logged-in to view this content.

FDA Authorizes 23andMe Direct-To-Consumer Pharmacogenetic Reports

You must be logged-in to view this content.

Evolving Pharmacology Of Depression: Beyond The Monoamine Hypothesis

According to the World Health Organization, major depressive disorder (MDD) currently impacts 300 million individuals worldwide and is the leading …

You must be logged-in to view this content.

Neuromodulation Techniques: State Of The Science

Clinicians managing patients with behavioral health issues are presented with various diagnostic and treatment challenges, spanning the areas of neurobiology, …

You must be logged-in to view this content.

Webinar Summary – Pharmacogenomics & Personalized Medicine: Where Are We Now & Where Are We Going?

You must be logged-in to view this content.

Recognition & Treatment Of Mood Disorders In Primary Care: Highlighting Integrated Care Between The Pharmacist & Physician

The primary care setting is often the default for treatment of mood disorders, but primary care physicians can become overwhelmed …

You must be logged-in to view this content.

Pharmacogenomics & Personalized Medicine: Where Are We Now & Where Are We Going?

In this webinar, Henry A. Nasrallah, MD and Rifaat El-Mallakh, MD, review foundational concepts related to the cytochrome p-450 system …

You must be logged-in to view this content.

Webinar Summary – Future Of Psychopharmacology: Is New Treatment Innovation Still Alive?

This summary was developed utilizing the full recorded presentation of this virtual forum, which is available on PsychU for all …

You must be logged-in to view this content.

Follow Up Q&A – Treatment Of Schizophrenia: Focus On Psychopharmacology & Adherence

During this question and answer session, Henry A. Nasrallah, MD and Roger Sommi, PharmD, BCPP, FCCP respond to unanswered questions …

You must be logged-in to view this content.

Webinar Summary – Treatment Of Schizophrenia: Focus On Psychopharmacology & Adherence

This summary was developed utilizing the full recorded presentation of this webinar, which is available on PsychU for all members …

You must be logged-in to view this content.

Do Inflammation & Metabolic Disturbances Metastasize To The Brain? Implications For Disease Modeling & Novel Approaches In Psychiatry (Inflammation Series Part 1)

During this webinar, Dr. Roger S. McIntyre, Professor of Psychiatry and Pharmacology (University of Toronto), Head of the Mood Disorders …

You must be logged-in to view this content.

Cost Of Illness For Bipolar Disorder: A Systematic Review Of The Economic Burden

You must be logged-in to view this content.

Glutamate Metabolism In Major Depressive Disorder

You must be logged-in to view this content.

Suboptimal Response In Psychotic & Mood Disorders: Causes, Consequences, & Management Strategies

Suboptimal response is a common challenge and can lead to negative consequences for patients diagnosed with serious mental illness. In …

You must be logged-in to view this content.